Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia

Current Medical Research and Opinion

Volumn 30, Issue 7, 2014, Pages 1201-1207

  Verbalis, Joseph G ^a   Grossman, Ashley ^b   Höybye, Charlotte ^c   Runkle, Isabelle ^d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Conivaptan; Guidelines; Hyponatremia; Mozavaptan; Sodium; Syndrome of inappropriate anti diuretic hormone secretion (SIADH); Tolvaptan

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; LITHIUM; LOOP DIURETIC AGENT; MOZAVAPTAN; TOLVAPTAN; UREA; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTICLE; CLINICAL PRACTICE; CONSENSUS; DECISION MAKING; FLUID INTAKE; HEART EDEMA; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY POLYCYSTIC DISEASE; LIQUID; MARKETING; NEOPLASM; PHYSICIAN; PRACTICE GUIDELINE; SAFETY; FLUID THERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; COMBINED MODALITY THERAPY; CONSENSUS; FLUID THERAPY; HUMANS; HYPONATREMIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84903600600     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.920314     Document Type: Article

References (20)

1. Flear CT, Gill GV, Burn J. Hyponatraemia: Mechanisms and management. Lancet 1981;2:26-31 (Pubitemid 11038688
2. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169-72 (Pubitemid 37329815
3. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: Prevalence, causes and consequences. Eur J Endocrinol 2010;162(Suppl 1):S5-12
4. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008;24:1601-8 (Pubitemid 351929058
5. Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol 2009;29:227-38
6. Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: Evidence from a meta-Analysis. PLoS ONE 2013;8:e80451
7. Gill G, Huda B, Boyd A, et al. Characteristics and mortality of severe hyponatraemia-A hospital-based study. Clin Endocrinol (Oxf) 2006;65:246-9 (Pubitemid 44079690
8. Wald R, Jaber BL, Price LL, et al. Impact of hospital-Associated hyponatremia on selected outcomes. Arch Intern Med 2010;170:294-302
9. Hoorn EJ, Rivadeneira F, van Meurs JB, et al. Mild hyponatremia as a risk factor for fractures: Uhe Rotterdam Study. J Bone Miner Res 2011;26:1822-8
10. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. Am J Med 2013;126(10 Suppl 1):S1-42
11. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014;29(Suppl 2):i1-i39
12. Chantzichristos D, Drougge H, Dahm P, et al. Svenska Endokrinologfö reningen. Available at: Http://endokrinologforeningen.se/ index.php/nyheter/52- 2012-02-09-svenskt-vardprogram-for-hyponatremi. Accessed April 2, 2014
13. Runkle I, Navarro A, Pose A, et al. El tratamiento de la hiponatremia secundaria al síndrome de secreció n inadecuada de la hormona antidiuré tica. Med Clin (Barc) 2013;141:507.e1-507.e10
14. Grossman A, Bouloux PM, Thatcher N, et al. Expert panel guidelines for the treatment of hyponatraemia. Draft version, presented at Stratford, UK, February 7-8, 2013
15. Samsca (Tolvaptan): Drug Safety Communication-FDA limits duration and usage due to possible liver injury leading to organ transplant or death. Available at: Http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm350185.htm. Accessed April 30, 2013
16. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529-42
17. Soupart A, Coffernils M, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-Term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7:742-7
18. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112 (Pubitemid 44749318
19. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-32
20. Bichet DG. What is the role of vaptans in routine clinical nephrology? Clin J Am Soc Nephrol 2012;7:700-3.